"10.1371_journal.pone.0112188","plos one","2014-11-11T00:00:00Z","Michael Mauer; Emily Glynn; Einar Svarstad; Camilla Tøndel; Marie-Claire Gubler; Michael West; Alexey Sokolovskiy; Chester Whitley; Behzad Najafian","Department of Pediatrics, University of Minnesota, Minneapolis, United States of America; Department of Medicine, University of Minnesota, Minneapolis, United States of America; Department of Pathology, University of Washington, Seattle, United States of America; Department of Medicine, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Pediatrics, Haukeland University Hospital, Bergen, Norway; U983, Université René Descartes, Hôpital Necker-Enfants Malades AP-HP, Paris, France; Division of Nephrology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada","Conceived and designed the experiments: MM BN. Performed the experiments: MM EG AS BN. Analyzed the data: AS BN. Contributed reagents/materials/analysis tools: MM ES CT MG MW CW. Contributed to the writing of the manuscript: MM BN EG ES CT MG AS MW CW.","BN is a consultant to Genzyme and Amicus Therapeutics, receives investigator initiated research support from Genzyme and Roche, and honoraria and travel support from Genzyme. BN is also a member of the Medical Advisory Board of Amicus Therapeutics. MM is a consultant to Genzyme, and receives investigator initiated research support, honoraria, and travel support from Genzyme. MM is also a member of the Genzyme funded FDA mandated Fabry Registry Board. This interest for MM has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies. MM is also a consultant to Amicus. CT and ES received travel support and speakers honoraria from Shire and Genzyme. MLW has received research support, honoraria, and/or travel support from Actelion, Amicus, Excelsior Pharmaceuticals, Genzyme, Glaxo SmithKline, Shire, and Sumitomo Pharma. Behzad Najafian is a PLOS ONE Editorial Board member, and commercial affiliations do not alter the authors' adherence to PLOS ONE Editorial policies and criteria.","2014","11","Michael Mauer","MM",9,TRUE,2,4,2,NA,TRUE,FALSE,FALSE,0,NA,FALSE
